Transaction · 0001741533-26-000012

Paolini John F.

Paolini John F., CMO, reported a transaction classified as exercise at Kiniksa Pharmaceuticals International, plc involving 11958.000000 shares for an estimated $214287.36. Reported holdings after the transaction were 88335.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCMO
KNSAKiniksa Pharmaceuticals International, plc
Trade date
Nov 02, 2026
Filing date
Nov 03, 2026
View on SEC Insider profile
Disclosed value$214kShares × reported price
Shares traded11.9k$17.92 per share
Holdings after88.3kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

KNSA price since this filing

Daily closing prices, with the filing date and available return windows
KNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -20.4%1w ago -23.3%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001741533-26-000012
Class A Ordinary Share
Transaction date
Nov 02, 2026
Filed Nov 03, 2026, 11:28 PM · 1d delay
Shares
11,958 sh
$17.92 per share
Estimated value
$214k
Computed from shares × price
Holdings after
88,335 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF MEDICAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 29, 2026.

  2. F2

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.3575 and $92.355. The price reported in this column reflects a weighted average sales price. Upon…

  3. F3

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.36 and $93.35. The price reported in this column reflects a weighted average sales price. Upon re…

  4. F4

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.385. The price reported in this column reflects a weighted average sales price. Upon r…

  5. F5

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.24. The price reported in this column reflects a weighted average sales price. Upon re…

  6. F6

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.465. The price reported in this column reflects a weighted average sales price. Upon…

  7. F7

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.415. The price reported in this column reflects a weighted average sales price. Upon…

  8. F8

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.30. The price reported in this column reflects a weighted average sales price. Upon re…

  9. F9

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.00 and $92.805. The price reported in this column reflects a weighted average sales price. Upon r…

  10. F10

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.02 and $94.00. The price reported in this column reflects a weighted average sales price. Upon re…

  11. F11

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.025 and $94.135. The price reported in this column reflects a weighted average sales price. Upon…

  12. F12

    The option is fully vested and exercisable.

Original filing · 0001741533-26-000012
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

KNSA